Summary
Eleven patients with heavily pretreated acute leukaemia were treated with 4-demethoxydaunorubicin. Dosages were escalated from 7 mg/m2/d to 15 mg/m2/d for 3 consecutive days. One patient achieved a partial remission and antitumor activity was seen in most other patients. Stomatitis was dose-limiting at 15 mg/m2. Phase II trials are warranted and we propose a schedule of 12 mg/m2/d for 3 consecutive days.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Sauter Chr, Berchtold W, Fopp M, Gratwohl A, Imbach P, Maurice P, Tschopp L, Von Fliedner V, Cavalli F: Acute myelogenous leukaemia: maintenance chemotherapy after early consolidation treatment does not prolong survival. Lancet 1:379–382, 1984
Tschopp L, Sauter C, Fopp M, Von Fliedner V, Cavalli F: MAMSA, etoposide ± vinblastine combination for relapsing and resistant acute non-lymphocytic leukemia (Abstract). Cancer Chemother Pharmacol 14 (Supplement):64, 1984
Rudnick SA, Cadman EC, Capizzi RL, Skeel RT, Bertino JR, McIntosh S: High-dose cytosine arabinoside (HDARAC) in refractory acute leukemia. Cancer 44:1189–1193, 1979
Arcamone F, Bernardi L, Giardino P, Dasdia T, Di Marco A: Synthesis and antitumor activity of 4-demethoxydaunorubicin, 4-demethoxy-7,9-diepidaunorubicin, and their β-anomers. Cancer Treat Rep 60:829–834, 1976
Supino R, Necco A, Dasdia T, Casazza AM, Di Marco A: Relationship between effects on nucleic acid synthesis in cell cultures and cytotoxicity of 4-demethoxyderivatives of daunorubicin and adriamycin. Cancer Res 37:4523–4528, 1977
Kaplan S, Martini A, Varini M, Togni P, Cavalli F: Phase I trial of 4-demethoxydaunorubicin with single i.v. doses. Eur J Cancer Clin Oncol 18:1303–1306, 1982
Kaplan S, Sessa C, Willems Y, Pacciarini MA, Tamassia V, Cavalli F: Phase I trial of 4-demethoxydaunorubicin (idarubicin) with single oral doses. Invest New Drugs 2:281–286, 1984
Casazza AM, Bertazzoli C, Pratesi G, Belloni O, Di Marco A: Antileukemic activity and cardiac toxicity of 4-demethoxydaunorubicin (4-DM) (Abstract). Proc Am Assoc Cancer Res 20:16, 1979
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sessa, C., Tschopp, L., Fopp, M. et al. Phase-I trial of 4-demethoxydaunorubicin in acute leukaemias. Invest New Drugs 3, 357–359 (1985). https://doi.org/10.1007/BF00170758
Issue Date:
DOI: https://doi.org/10.1007/BF00170758